| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Enliven Therapeutics, Inc. (ELVN) has 10 insiders with recent SEC Form 4 filings, including 0 buys and 18 sells. ELVN is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 890.4K | $41.74M | - | |
| CEO | 875.0K | $41.02M | - | |
| Other | 740.2K | $34.70M | - | |
| 10% | 245.7K | $11.52M | -281,408 | |
| COO | 215.0K | $10.08M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 11, 2024 | Lyssikatos Joseph P50 | Chief Scientific Officer | Sale+OE | 30,000 | $25.04 | $751,332.00 | -100% | -3.2% | -30.7% | |
| Apr 11, 2024 | Ballal Rahul D.70 | Director | Sale+OE | 67,000 | $23.36 | $1,564,812.27 | -36.7% | -3.2% | -30.7% | |
| Apr 8, 2024 | Patel Anish54 | Chief Operating Officer | Sell | 4,875 | $18.60 | $90,686.79 | -45.9% | +22.7% | -13.6% | |
| Apr 4, 2024 | Ballal Rahul D.70 | Director | Sale+OE | 3,485 | $19.15 | $66,729.39 | -13.5% | +15.9% | +0.5% | |
| Apr 1, 2024 | Ballal Rahul D.70 | Director | Sale+OE | 3,237 | $19.08 | $61,758.40 | -12.7% | +20.1% | -0.1% | |
| Apr 1, 2024 | Lyssikatos Joseph P50 | Chief Scientific Officer | Sale+OE | 12,000 | $18.60 | $223,145.71 | -55.3% | +20.1% | -0.1% | |
| Mar 27, 2024 | Hohl Benjamin60 | Chief Financial Officer | Sale+OE | 3,250 | $18.25 | $59,302.37 | -94.7% | +15.2% | +15.5% | |
| Mar 25, 2024 | Kintz Samuel51 | President And CEO | Sale+OE | 12,000 | $17.56 | $210,661.12 | -72.0% | +22.8% | +19.9% | |
| Mar 20, 2024 | Ballal Rahul D.70 | Director | Sale+OE | 13,278 | $19.16 | $254,462.25 | -37.3% | +6.6% | +8.9% | |
| Mar 19, 2024 | Heyman Richard A.74 | Director | Sell | 1,270 | $14.50 | $18,418.68 | -0.9% | +22.9% | +19.1% |